Hepatitis C News

SAN FRANCISCO — Mavyret was highly effective and well-tolerated in patients with chronic hepatitis C genotype 1 who had experience with a combination of Sovaldi, NS5A inhibitor and ribavirin, according to data presented at The Liver Meeting 2018.

Recent incarceration is associated with an 81% increased risk for HIV and a 62% increased risk for hepatitis C virus acquisition, according to a systematic review and meta-analysis of dozens of studies from five continents.

AbbVie announced a new interactive online resource, MappingHepC.com, that features national and state-level data on hepatitis C screening, diagnosis and treatment, according to a press release.

WHO has released evidence-based guidelines for managing physical health conditions in adults with severe mental disorders, according to a press release.

Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral therapy, according to a recently published study.

Data from Australia’s annual bio-behavioral surveillance of people who inject drugs attending needle syringe programs between 2015 and 2017 showed a significant increase in hepatitis C treatment uptake and decrease in viremic prevalence, especially among older patients and those with a history of opioid substitution therapy.

Maternal neutralizing antibody responses have a role in preventing vertical transmission of hepatitis C virus, but not among women coinfected with HIV, according to study findings published in The Journal of Infectious Diseases.

Daklinza with Sovaldi and ribavirin produced similar rates of sustained virologic response among patients with hepatitis C genotypes 2 and 3 as those treated with Epclusa, according to a recently published study.

Fresenius Kidney Care developed a hepatitis C eradication program that resulted in a 97% cure rate among patients on dialysis who received direct-acting antiviral therapy.

The Canadian Minister of Health announced that the Government of Canada will fund 28 projects across the country designed to reduce the risk for bloodborne infections, such as hepatitis C and HIV, among people who use injection drugs, according to a press release.